JCXH-211
- Generic Name
- JCXH-211
Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma
Phase 1
Not yet recruiting
- Conditions
- Recurrent or Progressive High-grade Glioma
- Interventions
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Duke University
- Target Recruit Count
- 21
- Registration Number
- NCT06468605
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Malignant Solid TumorCutaneous Tumor
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Immorna Biotherapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05539157
- Locations
- 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath